Mode
Text Size
Log in / Sign up
N/A Completed N=519

Evaluation of the Effectiveness, Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients

Osteoarthritis · Postoperative Pain · Morning Stiffness
Source: ClinicalTrials.gov NCT01226095 ↗
Enrolled (actual)
519
Serious AEs
0.0%
Results posted
Jan 2012
Primary outcomePrimary: Day and Night Mean Pain Score for the Previous 24 Hours on a Nine-point Scale (0 = no Pain to 8 = Very Severe Pain) at Visit 3 (4 Weeks Following Treatment) in Comparison to Baseline. — 6.12; 2.10 units on a scale — p=<0.0001

Summary

This is a prospective, multi-center, post-marketing observational study to evaluate the effectiveness and compliance of ibuprofen in a sustained release form in the treatment of Egyptian osteoarthritic patients.

Outcome Measures

OutcomeResultp-value
PRIMARY
Day and Night Mean Pain Score for the Previous 24 Hours on a Nine-point Scale (0 = no Pain to 8 = Very Severe Pain) at Visit 3 (4 Weeks Following Treatment) in Comparison to Baseline.
6.12; 2.10 <0.0001 sig
PRIMARY
Number of Participants Who Improved (Reduced Pain), Had no Change (Equal Scores at Baseline and Visit), and Worsened (Increased Pain) at Visit 3 (After 4 Weeks of Treatment).
516; 3; 0 —
SECONDARY
Percent of Participant Compliance
99.39; 97.71; 98.55 —
SECONDARY
Number of Participants With Joint Tenderness/Stiffness at Each Visit
17; 87; 262; 75; 271; 210 —
SECONDARY
Number of Participants Who Improved (Reduced), Had no Change (Equal at Baseline and Visit), and Worsened (Increased) in Joint Tenderness/Stiffness at Visit 2 (After 2 Weeks of Treatment) and Visit 3 (After 4 Weeks of Treatment).
410; 473; 109; 46; 0; 0 —
SECONDARY
Duration of Morning Stiffness
24.20; 13.49; 7.76 —
SECONDARY
Number of Participants With 80% Reduction From Baseline in Duration of Morning Stiffness at Visit 2 (2 Weeks of Treatment) and Visit 3 (4 Weeks of Treatment)
58; 211; 429; 269 —
SECONDARY
Number of Participants With the Ability to Carry Out Normal Activities at Each Visit
172; 381; 471; 347; 138; 48 —
SECONDARY
Number of Participants Who Experienced Adverse Events and Serious Adverse Events
0; 41 —

Eligibility Criteria

Inclusion Criteria

  • Patients seeking treatment for osteoarthritis and there are clinical or radiological evidence of the disease,
  • Male or female, age ≥ 18
  • Designated to treatment with Ibuprofen in a sustained release form (Brufen Retard) according to the best criterion of the physician and if he decides to treat the patient according to labeled indication and dose for 4 weeks.
  • Patients who have given their written informed consent to participate in the study
  • Patients who are currently taking non steroidal anti inflammatory drugs (NSAIDs), should complete an initial washout phase 10 days depending on the half life of the drug taken

Exclusion Criteria

  • Contraindications as described in company core data sheet (CCDS) and specifically
  • Patients with active peptic ulcer
  • Patients who have presented reactions of hypersensitivity (asthma , rhinitis or urticaria ) with ibuprofen or other anti-inflammatory non steroids
  • Patients with active cardiovascular disease and those taking aspirin/warfarin for prophylaxis for myocardial infarction (MI) or stroke
  • Patients with moderate to severe renal diseases
  • Patients with moderate to severe hepatic disease
  • Patients with Crohn's disease
  • Patients included currently in another study
  • Women of childbearing potential must not be pregnant
  • Any patients the investigators consider ineligible for this study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01226095). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search